Cancer Research and Treatment

Original Articles

Breast cancer

Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor–Positive Metastatic Breast Cancer: Seul-Gi Kim, Min Hwan Kim, Sejung Park, Gun Min Kim, Jee Hung Kim, Jee Ye Kim, Hyung Seok Park, Seho Park, Byeong Woo Park, Seung Il Kim, Jung Hwan Ji, Joon Jeong, Kabsoo Shin, Jieun Lee, Hyung-Don Kim, Kyung Hae Jung, Joohyuk Sohn; Cancer Res Treat. 2023;55(4):1198-1209. Published online April 11, 2023; DOI: https://doi.org/10.4143/crt.2022.1543

Abstract PDF Supplementary Material PubReader ePub

Purpose
Frequent neutropenia hinders uninterrupted palbociclib treatment in patients with hormone receptor (HR)–positive breast cancer. We compared the efficacy outcomes in multicenter cohorts of patients with metastatic breast cancer (mBC) receiving palbociclib following conventional dose modification or limited modified schemes for afebrile grade 3 neutropenia.
Materials and Methods
Patients with HR-positive, human epidermal growth factor receptor 2–negative mBC (n=434) receiving palbociclib with letrozole as first-line therapy were analyzed and classified based on neutropenia grade and afebrile grade 3 neutropenia management as follows: group 1 (maintained palbociclib dose, limited scheme), group 2 (dose delay or reduction, conventional scheme), group 3 (no afebrile grade 3 neutropenia event), and group 4 (grade 4 neutropenia event). The primary and secondary endpoints were progression-free survival (PFS) between groups 1 and 2 and PFS, overall survival, and safety profiles among all groups.
Results
During follow-up (median 23.7 months), group 1 (2-year PFS, 67.9%) showed significantly longer PFS than did group 2 (2-year PFS, 55.3%; p=0.036), maintained across all subgroups, and upon adjustment of the factors. Febrile neutropenia occurred in one and two patients of group 1 and group 2, respectively, without mortality.
Conclusion
Limited dose modification for palbociclib-related grade 3 neutropenia may lead to longer PFS, without increasing toxicity, than the conventional dose scheme.

Citations

Citations to this article as recorded by

Palbociclib in Patients With HR+/HER2− Advanced or Metastatic Breast Cancer and Bone-Only Metastasis: A Systematic Literature Review
Joyce O’Shaughnessy, Nusrat Jahan, Anna Louise Barry, Rebecca Jean Watters, Beata Korytowsky, Diana Avery, Vinay Pasupuleti, Andrew Proctor
Clinical Breast Cancer.2026; 26(6): 113. CrossRef
Efficacy and Safety of Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Real-World Studies
Hui-Chen Su, Ho-Wei Lin, Ka-Wai Tam
Targeted Oncology.2025; 20(1): 71. CrossRef
Palbociclib Is Safe for Breast Cancer Patients With Mild Hepatic Impairment: A Multicenter Retrospective Study Using Real‐World Data
Alieke K. Bos, Annelieke E.C.A.B. Willemsen, Loes E. Visser, Lennart J. Stoker, Jurjen S. Kingma, Mirjam K. Rommers, Emile M. Kuck, Paul D. van der Linden, Merel van Nuland
Clinical Pharmacology & Therapeutics.2025; 117(4): 1115. CrossRef
Real-world effectiveness of CDK4/6i in first-line treatment of HR+/HER2− advanced/metastatic breast cancer: updated systematic review
Nadia Harbeck, Adam Brufsky, Chloe Grace Rose, Beata Korytowsky, Connie Chen, Krista Tantakoun, Endri Jazexhi, Do Hoang Vien Nguyen, Meaghan Bartlett, Imtiaz A. Samjoo, Timothy Pluard
Frontiers in Oncology.2025;[Epub] CrossRef
Adverse Event Costs and Cost-Effectiveness Analyses of Anticancer Drugs
Mingye Zhao, Taihang Shao, Yue Yin, Hongshu Fang, Hanqiao Shao, Wenxi Tang
JAMA Network Open.2025; 8(5): e2512455. CrossRef
Palbociclib treatment in patients with HR+/HER2− advanced or metastatic breast cancer and visceral metastasis: A systematic literature review
Julia C. Radosa, Sara López-Tarruella Cobo, Johanna Dzieran, Esther Glastetter, Connie Chen, Melissa Lingohr-Smith, Vinay Pasupuleti, Adam Brufsky
The Breast.2025; 84: 104569. CrossRef
Palbociclib

Reactions Weekly.2023; 1988(1): 138. CrossRef

9,799 View
306 Download
6 Web of Science
7 Crossref

A Phase II Study to Evaluate the Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients Receiving Dose-Dense Doxorubicin/Cyclophosphamide: Gun Min Kim, Joo Hoon Kim, Ji Heung Kim, Young Up Cho, Seung Il Kim, Seho Park, Hyung Seok Park, Ji Ye Kim, Joohyuk Sohn; Cancer Res Treat. 2019;51(2):812-818. Published online September 19, 2018; DOI: https://doi.org/10.4143/crt.2018.383

Abstract PDF PubReader ePub

Purpose
Dose-dense chemotherapy (DD-CT) is a preferred (neo)adjuvant regimen in early breast cancer (BC). Although the results of reported randomized trials are conflicting, a recent metaanalysis showed improved overall and disease-free survival with DD-CT compared to conventional schedules. However, no DD-CT safety data for Korean BC patients are available. This phase II study was conducted to evaluate the safety and efficacy of pegteograstim in Korean BC patients receiving DD-CT.
Materials and Methods
Patients with operable (stage I-III), histologically confirmed BC received four cycles of intravenous doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) on day 1 every 2 weeks as neoadjuvant or adjuvant therapy. Pegteograstim (6.0 mg) was administered subcutaneously on day 2 of each cycle. The primary endpoint was the incidence of febrile neutropenia (FN). The secondary endpoints were safety and tolerability.
Results
Of 63 patients, one (1.6%) developed FN during all cycles of DD-CT. Dose delay was observed in four patients (6.3%) and dose reduction in two (3.2%) during DD-CT. Frequent adverse events (AEs) were nausea, alopecia, generalized muscle weakness, myalgia, mucositis, anorexia, dyspepsia, and diarrhea; most AEs were related to chemotherapy. Grade 3-4 AEs were reported in five of 63 patients (7.9%), and all grade 3 and 4 AEs were related to chemotherapy. Adverse drug reactions possibly linked to pegteograstim were abdominal pain, bone pain, myalgia, generalized muscle weakness, and headache in five of 63 patients (7.9%).
Conclusion
Dose-dense AC (doxorubicin/cyclophosphamide) chemotherapywith pegteograstim support is a tolerable and safe regimen in Korean early BC patients.

Citations

Citations to this article as recorded by

Chemotherapy-Induced Alopecia in Breast Cancer Patients: Treatment-Specific Incidence and Risk of Persistent Hair Loss
Simonetta I. Gaumond, Sophie Shrestha, Isabella Kamholtz, Gabriela E. Beraja, Joaquin J. Jimenez
Cancers.2026; 18(5): 861. CrossRef
Comprehensive toxicity profile of the 4AC-4THP neoadjuvant regimen in HER2-positive breast cancer: a multicenter real-world study in Vietnam
Anh Dinh Tran, Le Huy Trinh, Tuan Anh Pham
Frontiers in Oncology.2026;[Epub] CrossRef
Local dose-dense chemotherapy for triple-negative breast cancer via minimally invasive implantation of 3D printed devices
Noehyun Myung, Hyun-Wook Kang
Asian Journal of Pharmaceutical Sciences.2024; 19(1): 100884. CrossRef
Safety and Efficacy of Pegteograstim on Chemotherapy-induced Neutropenia in Children and Adolescents With Solid Tumors
Hee Won Cho, Ji Won Lee, Hee Young Ju, Ju Kyung Hyun, Keon Hee Yoo, Hong Hoe Koo, Kyunga Kim, Ki Woong Sung
Journal of Pediatric Hematology/Oncology.2022; 44(2): e362. CrossRef
Prophylaxis and treatment strategies for optimizing chemotherapy relative dose intensity
Michelle Shayne, R. Donald Harvey, Gary H. Lyman
Expert Review of Anticancer Therapy.2021; 21(10): 1145. CrossRef

10,382 View
275 Download
5 Web of Science
5 Crossref

Feasibility of Charcoal Tattooing of Cytology-Proven Metastatic Axillary Lymph Node at Diagnosis and Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients: Seho Park, Ja Seung Koo, Gun Min Kim, Joohyuk Sohn, Seung Il Kim, Young Up Cho, Byeong-Woo Park, Vivian Youngjean Park, Jung Hyun Yoon, Hee Jung Moon, Min Jung Kim, Eun-Kyung Kim; Cancer Res Treat. 2018;50(3):801-812. Published online August 17, 2017; DOI: https://doi.org/10.4143/crt.2017.210

Abstract PDF PubReader ePub

Purpose
Sentinel lymph node biopsy (SLNB) can be performed when node-positive disease is converted to node-negative status after neoadjuvant chemotherapy (NCT). Tattooing nodes might improve accuracy but supportive data are limited. This study aimed to investigate the feasibility of charcoal tattooing metastatic axillary lymph node (ALN) at presentation followed by SLNB after NCT in breast cancers.
Materials and Methods
Twenty patientswith cytology-proven node metastases prospectively underwent charcoal tattooing at diagnosis. SLNB using dual tracers and axillary surgery after NCT were then performed. The detection rate of tattooed node and diagnostic performance of SLNB were analyzed.
Results
All patients underwent charcoal tattooingwithout significant morbidity. Sentinel and tattooed nodes could be detected during surgery after NCT. Nodal pathologic complete response was achieved in 10 patients. Overall sensitivity, false-negative rate (FNR), negative predictive value, and accuracy of hot/blue SLNB were 80.0%, 20.0%, 83.3%, and 90.0%, respectively. Retrieving more nodes and favorable nodal response were associated with improved performance. The best accuracy was observed when excised tattooed node was calculated together (FNR, 0.0%). Cold/non-blue tattooed nodes of five patients were removed during non-sentinel axillary surgery but clinicopathological parameters did not differ compared to patients with hot/blue tattooed node detected during SLNB, suggesting the importance of the tattooing procedure itself to improve performance.
Conclusion
Charcoal tattooing of cytology-confirmed metastatic ALN at presentation is technically feasible and does not limit SLNB after NCT. The tattooing procedure without additional preoperative localization is advantageous for improving the diagnostic performance of SLNB in this setting.

Citations

Citations to this article as recorded by

Charcoal localization of metastatic axillary lymphadenopathy in breast cancer patients: concordance with sentinel lymph node biopsy
Sepideh Mousavian, Samaneh Sajjadi, Farzaneh Khoroushi, Sahar Ravanshad, Mona Kabiri, Ali Moradi, Mohammad Naser Forghani, Seyed Abbas Tabatabaee Yazdi, Mohsen Mohammadzadeh, Maryam Tavakkoli, Seyed-Ali Alamdaran
Breast Cancer.2026; 33(4): 938. CrossRef
Indocyanine Green Fluorescence Plus Blue Dye for Sentinel Lymph Node Biopsy in Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer: A Multicenter, Prospective Cohort Study
Miao Liu, Yang Yang, Bin Hua, Rui Feng, Tianyu Xu, Mengyuan Wang, Xiaowei Qi, Yingming Cao, Bo Zhou, Fuzhong Tong, Peng Liu, Hongjun Liu, Lin Cheng, Houpu Yang, Fei Xie, Siyuan Wang, Chaobin Wang, Yuan Peng, Danhua Shen, Lei Chen, Jun Jiang, Shu Wang
Thoracic Cancer.2025;[Epub] CrossRef
The efficacy and oncological safety of minimally invasive axillary procedures in patients with node-positive breast cancer receiving neoadjuvant chemotherapy: A network meta-regression and trial sequential analysis
James Lucocq, Hassan Baig, Esther McNeill, J Michael Dixon
European Journal of Surgical Oncology.2025; 51(7): 109689. CrossRef
Targeted Axillary Dissection for Clinically Node-Positive Breast Cancer Cases that Turn Negative After Neoadjuvant Systemic Therapy Using Charcoal Tattooing
Mohamed Yousri, Ashraf Khater, Waleed Elnahas, Osama Eldamshety, Eman Alnaghy, Mohamed Ezzat
Indian Journal of Surgical Oncology.2025; 16(6): 1705. CrossRef
Radiographic identification of a positive clipped axillary lymph node in a mastectomy specimen following neoadjuvant chemotherapy
Andrew Seto, Cynthia Lin, Samantha Norden, Jamie Stratton, Moira O'Riordan, Helen Pass
Radiology Case Reports.2024; 19(1): 435. CrossRef
Peut-on surseoir au curage axillaire en cas de carcinome mammaire invasif avec envahissement ganglionnaire ?
Susie Brousse, Clémentine Lafond, Martin Schmitt, Sophie Guillermet, Sébastien Molière, Carole Mathelin
Gynécologie Obstétrique Fertilité & Sénologie .2024; 52(3): 132. CrossRef
The Role of Level III Dissection in Locally Advanced Breast Cancer following Neoadjuvant Chemotherapy—A Prospective Study
Rexeena V. Bhargavan, Nisha Prasannan, K.M. Jagathnath Krishna, Paul Augustine, Kurian Cherian
South Asian Journal of Cancer.2024; 13(03): 170. CrossRef
Melanin-Based Nanoparticles for Lymph Node Tattooing: Experimental, Histopathological and Ultrastructural Study
Marta Baselga, Antonio Güemes, Cristina Yus, Teresa Alejo, Víctor Sebastián, Dolores Arribas, Gracia Mendoza, Eva Monleón, Manuel Arruebo
Nanomaterials.2024; 14(13): 1149. CrossRef
Utility of a breast biopsy clip and a point marker system in tailored axillary surgery for patients with breast cancer after neoadjuvant chemotherapy
Yuka Endo, Haruru Kotani, Nobuko Tamura, Kiyo Tanaka, Chiho Kudo, Masataka Sawaki, Masaya Hattori, Akiyo Yoshimura, Ayumi Kataoka, Kazuki Nozawa, Yuri Ozaki, Ayaka Isogai, Rie Komaki, Akira Nakakami, Nari Kureyama, Maho Kusudo, Waki Hosoda, Hidetaka Kawab
Breast Cancer.2024; 31(6): 1130. CrossRef
Oncological outcomes of selective axillary dissection with 4% carbon marking
LUCAS ROSKAMP BUDEL, CLEVERTON CÉSAR SPAUTZ, MARIA HELENA LOUVEIRA, TERESA CRISTINA SANTOS CAVALCANTI, ALESSANDRA CORDEIRO FORNAZARI, PLINIO GASPERIN JUNIOR, LEONARDO NISSEN, VINICIUS MILANI BUDEL
Revista do Colégio Brasileiro de Cirurgiões.2024;[Epub] CrossRef
Desfechos oncológicos da dissecção axilar seletiva utilizando carvão a 4% como marcador
LUCAS ROSKAMP BUDEL, CLEVERTON CÉSAR SPAUTZ, MARIA HELENA LOUVEIRA, TERESA CRISTINA SANTOS CAVALCANTI, ALESSANDRA CORDEIRO FORNAZARI, PLINIO GASPERIN JUNIOR, LEONARDO NISSEN, VINICIUS MILANI BUDEL
Revista do Colégio Brasileiro de Cirurgiões.2024;[Epub] CrossRef
Preclinical evaluation of polymer encapsulated carbon-based nano and microparticles for sentinel lymph node tattooing
Marta Baselga, Antonio Güemes, Manuel Arruebo, Cristina Yus, Teresa Alejo, Víctor Sebastián, Gema Martínez, Dolores Arribas, Gracia Mendoza, Concepción Junquera, Eva Monleón
Scientific Reports.2024;[Epub] CrossRef
Biopsia del ganglio centinela y disección axilar dirigida en mujeres con cáncer de mama y axila positiva en el momento del diagnóstico: caminando hacia el futuro
Paula Moral Rubio, Silvia Delgado García, Hortensia Ballester Galiana, Jose Ponce Lorenzo, Tina Martín Bayón, Gloria Peiró
Revista de Senología y Patología Mamaria.2023; 36(1): 100402. CrossRef
Estadificación ganglionar tras terapia sistémica primaria en mujeres con cáncer de mama y afectación ganglionar al diagnóstico
Eva Acea-Figueira, Alejandra García-Novoa, Carlota Díaz Carballada, Alberto Bouzón Alejandro, Carmen Conde, Paz Santiago Freijanes, Joaquín Mosquera Oses, Benigno Acea-Nebril
Cirugía Española.2023; 101(6): 417. CrossRef
Lymph node staging after primary systemic therapy in women with breast cancer and lymph node involvement at diagnosis
Eva Acea-Figueira, Alejandra García-Novoa, Carlota Díaz Carballada, Alberto Bouzón Alejandro, Carmen Conde, Paz Santiago Freijanes, Joaquín Mosquera Oses, Benigno Acea-Nebril
Cirugía Española (English Edition).2023; 101(6): 417. CrossRef
Carbon tattooing of axillary lymph nodes in breast cancer patients before neoadjuvant chemotherapy: A retrospective analysis
Mauro Porpiglia, Fulvio Borella, Pierluigi Chieppa, Carola Brino, Ada Ala, Vincenzo Marra, Isabella Castellano, Chiara Benedetto
Tumori Journal.2023; 109(3): 301. CrossRef
Concomitant Use of Biopsy Clips and Wire Localization in Invasive Breast Cancer is Associated With Successful Clip Retrieval
Jennifer H. Chen, Joe K. Canner, Kelly Myers, Melissa Camp
Clinical Breast Cancer.2023; 23(3): e163. CrossRef
Carbon nanoparticles localized clipped node dissection combined with sentinel lymph node biopsy with indocyanine green and methylene blue after neoadjuvant therapy in node positive breast cancer in China: initial results of a prospective study
Xin Yang, Yao Li, Xiao-tian Ren, Lei Fan, Bin Hua
World Journal of Surgical Oncology.2023;[Epub] CrossRef
Outcomes of Sentinel Node Biopsy for Women with Breast Cancer After Neoadjuvant Therapy: Systematic Review and Meta-Analysis of Real-World Data
Shi-Qian Lin, Nguyen-Phong Vo, Yu-Chun Yen, Ka-Wai Tam
Annals of Surgical Oncology.2022; 29(5): 3038. CrossRef
Nanoparticle-assisted axillary staging: an alternative approach after neoadjuvant chemotherapy in patients with pretreatment node-positive breast cancers
Jiqiao Yang, Tao He, Yunhao Wu, Zhoukai Fu, Qing Lv, Shan Lu, Xiaodong Wang, Hongjiang Li, Jing Wang, Jie Chen
Breast Cancer Research and Treatment.2022; 192(3): 573. CrossRef
Axillary Management: How Has Neoadjuvant Chemotherapy Changed Our Surgical Approach?
Mara A. Piltin, Judy C. Boughey
Current Breast Cancer Reports.2022; 14(1): 1. CrossRef
Gezielte Entfernung axillärer Lymphknoten nach Kohlenstoffmarkierung bei Patientinnen mit primär systemisch behandeltem Mammakarzinom
Steffi Hartmann, Angrit Stachs, Thorsten Kühn, Jana de Boniface, Maggie Banys-Paluchowski, Toralf Reimer
Senologie - Zeitschrift für Mammadiagnostik und -therapie.2022; 19(01): 49. CrossRef
Gezielte Entfernung axillärer Lymphknoten nach Kohlenstoffmarkierung bei Patientinnen mit primär systemisch behandeltem Mammakarzinom
Steffi Hartmann, Angrit Stachs, Thorsten Kühn, Jana de Boniface, Maggie Banys-Paluchowski, Toralf Reimer
TumorDiagnostik & Therapie.2022; 43(03): 197. CrossRef
False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant systemic therapy
Jana de Boniface, Jan Frisell, Thorsten Kühn, Ingrid Wiklander-Bråkenhielm, Karin Dembrower, Per Nyman, Athanasios Zouzos, Bernd Gerber, Toralf Reimer, Steffi Hartmann
Breast Cancer Research and Treatment.2022; 193(3): 589. CrossRef
Diagnostic accuracy of de‐escalated surgical procedure in axilla for node‐positive breast cancer patients treated with neoadjuvant systemic therapy: A systematic review and meta‐analysis
Yu‐xin Song, Zheng Xu, Ming‐xing Liang, Zhen Liu, Jun‐chen Hou, Xiu Chen, Di Xu, Yin‐jiao Fei, Jin‐hai Tang
Cancer Medicine.2022; 11(22): 4085. CrossRef
Multidisciplinary considerations in the management of breast cancer patients receiving neoadjuvant chemotherapy
Faina Nakhlis, Leah Portnow, Eva Gombos, Ayse Ece Cali Daylan, Jose Pablo Leone, Olga Kantor, Edward T. Richardson, Alice Ho, Samantha Armstrong Dunn, Nisha Ohri
Current Problems in Surgery.2022; 59(9): 101191. CrossRef
Combining Wire Localization of Clipped Nodes with Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer: Preliminary Results from a Prospective Study
Alejandra García-Novoa, Benigno Acea-Nebril, Carlota Díaz Carballada, Alberto Bouzón Alejandro, Carmen Conde, Carmen Cereijo Garea, José Ramón Varela, Paz Santiago Freijanes, Silvia Antolín Novoa, Lourdes Calvo Martínez, Inma Díaz, Sofia Rodríguez Martíne
Annals of Surgical Oncology.2021; 28(2): 958. CrossRef
A multicentre prospective feasibility study of carbon dye tattooing of biopsied axillary node and surgical localisation in breast cancer patients
Amit Goyal, Shama Puri, Andrea Marshall, Kalliope Valassiadou, Moin M. Hoosein, Amtul R. Carmichael, Gabriella Erdelyi, Nisha Sharma, Janet Dunn, Joanne York
Breast Cancer Research and Treatment.2021; 185(2): 433. CrossRef
Carbon tattooing for targeted lymph node biopsy after primary systemic therapy in breast cancer: prospective multicentre TATTOO trial
S Hartmann, T Kühn, J de Boniface, A Stachs, A Winckelmann, J Frisell, I Wiklander-Bråkenhielm, J Stubert, B Gerber, T Reimer
British Journal of Surgery.2021; 108(3): 302. CrossRef
Different strategies in marking axillary lymph nodes in breast cancer patients undergoing neoadjuvant medical treatment: a systematic review
Vivian Man, Ava Kwong
Breast Cancer Research and Treatment.2021; 186(3): 607. CrossRef
Sentinel lymph node BIOPSY after neoadjuvant therapy in breast cancer patients with lymph node involvement at diagnosis. Could wire localization of clipped node improve our results?
Marina Alarcón, Elvira Buch, Ana Julve, Marta Hernandorena, Marcos Tajahuerce, Héctor Rodríguez, Begoña Bermejo, Judith Ramírez, Octavio Burgués, Sandra Díaz, Gara M. Alcalá, Joaquín Ortega
The Surgeon.2021; 19(6): 344. CrossRef
The Evolving Role of Marked Lymph Node Biopsy (MLNB) and Targeted Axillary Dissection (TAD) after Neoadjuvant Chemotherapy (NACT) for Node-Positive Breast Cancer: Systematic Review and Pooled Analysis
Parinita K. Swarnkar, Salim Tayeh, Michael J. Michell, Kefah Mokbel
Cancers.2021; 13(7): 1539. CrossRef
New horizons in imaging and surgical assessment of breast cancer lymph node metastasis
Firouzeh Arjmandi, Ann Mootz, Deborah Farr, Sangeetha Reddy, Basak Dogan
Breast Cancer Research and Treatment.2021; 187(2): 311. CrossRef
Assessment of axillary node status by ultrasound after neoadjuvant chemotherapy in patients with clinically node-positive breast cancer according to breast cancer subtype
Yurina Maeshima, Takehiko Sakai, Akiko Ogiya, Yoko Takahashi, Yumi Miyagi, Yumi Kokubu, Tomo Osako, Yoshinori Ito, Shunji Takahashi, Shinji Ohno, Takayuki Ueno
Scientific Reports.2021;[Epub] CrossRef
Targeted axillary biopsy and sentinel lymph node biopsy for axillary restaging after neoadjuvant chemotherapy
Gunay Gurleyik, Sibel Aydin Aksu, Fügen Aker, Kubra Kaytaz Tekyol, Eda Tanrikulu, Emin Gurleyik
Annals of Surgical Treatment and Research.2021; 100(6): 305. CrossRef
Options to Determine Pathological Response of Axillary Lymph Node Metastasis after Neoadjuvant Chemotherapy in Advanced Breast Cancer
Vijayashree Murthy, Jessica Young, Yoshihisa Tokumaru, Marie Quinn, Stephen B. Edge, Kazuaki Takabe
Cancers.2021; 13(16): 4167. CrossRef
Influence of Imaging Features and Technique on US-guided Tattoo Ink Marking of Axillary Lymph Nodes Removed at Sentinel Lymph Node Biopsy in Women With Breast Cancer
Marlen Pajcini, Irene Wapnir, Jacqueline Tsai, Joanne Edquilang, Wendy DeMartini, Debra Ikeda
Journal of Breast Imaging.2021; 3(5): 583. CrossRef
Targeted Removal of Axillary Lymph Nodes After Carbon Marking in Patients with Breast Cancer Treated with Primary Chemotherapy
Steffi Hartmann, Angrit Stachs, Thorsten Kühn, Jana de Boniface, Maggie Banys-Paluchowski, Toralf Reimer
Geburtshilfe und Frauenheilkunde.2021; 81(10): 1121. CrossRef
Axillary Imaging Following a New Invasive Breast Cancer Diagnosis—A Radiologist’s Dilemma
Vandana Dialani, Basak Dogan, Katerina Dodelzon, Brian N Dontchos, Neha Modi, Lars Grimm
Journal of Breast Imaging.2021; 3(6): 645. CrossRef
Selective Extirpation of Tattooed Lymph Node in Combination with Sentinel Lymph Node Biopsy in the Management of Node-Positive Breast Cancer Patients after Neoadjuvant Systemic Therapy
Lukas Dostalek, Andrej Cerny, Petra Saskova, David Pavlista
Breast Care.2021; 16(6): 623. CrossRef
False Negativity of Targeted Axillary Dissection in Breast Cancer
George Kirkilesis, Anastasia Constantinidou, Michalis Kontos
Breast Care.2021; 16(5): 532. CrossRef
Synchronous early‑stage breast cancer and axillary follicular lymphoma diagnosed by core needle biopsy: A case report
Ryotaro Eto, Rikiya Nakamura, Naohito Yamamoto, Toshiko Miyaki, Shoko Hayama, Itaru Sonoda, Makiko Itami, Hideki Tsujimura, Hideyuki Hashimoto, Masayuki Otsuka
Molecular and Clinical Oncology.2021;[Epub] CrossRef
Breast and axillary surgery in malignant breast disease: a review focused on literature of 2018 and 2019
Nina Ditsch, Isabel T. Rubio, Maria L. Gasparri, Jana de Boniface, Thorsten Kuehn
Current Opinion in Obstetrics & Gynecology.2020; 32(1): 91. CrossRef
Targeted axillary dissection after neoadjuvant systemic therapy in patients with node‐positive breast cancer
Kavitha Kanesalingam, Nina Sriram, Ghaith Heilat, E ‐Ern Ng, Farid Meybodi, Elisabeth Elder, Meagan Brennan, James French
ANZ Journal of Surgery.2020; 90(3): 332. CrossRef
Initial results of a novel technique of clipped node localization in breast cancer patients postneoadjuvant chemotherapy: Skin Mark clipped Axillary nodes Removal Technique (SMART trial)
Geok Hoon Lim, Sze Yiun Teo, Mihir Gudi, Ruey Pyng Ng, Jinnie Pang, Yia Swam Tan, Yien Sien Lee, John C. Allen, Lester Chee Hao Leong
Cancer Medicine.2020; 9(6): 1978. CrossRef
Targeted axillary dissection of carbon‐tattooed metastatic lymph nodes in combination with post–neo‐adjuvant sentinel lymph node biopsy using 1% methylene blue in breast cancer patients
Emad Khallaf, Rasha Wessam, Mohamed Abdoon
The Breast Journal.2020; 26(5): 1061. CrossRef
Marking axillary nodes with 4% carbon microparticle suspension before neoadjuvant chemotherapy improves sentinel node identification rate and axillary staging
Cleverton Cesar Spautz, Eduardo Schunemann Junior, Lucas Roskamp Budel, Tereza Cristina Santos Cavalcanti, Maria Helena Louveira, Plinio Gasperin Junior, Leonardo Paese Nissen, Bernardo Passos Sobreiro, Maíra Teixeira Dória, Cicero Andrade Urban, Vinicius
Journal of Surgical Oncology.2020; 122(2): 164. CrossRef
Targeted Axillary Dissection for Patients Who Convert to Clinically Node Negative After Neoadjuvant Chemotherapy for Node-Positive Breast Cancer
Kandice Ludwig, Amanda L. Kong
Current Breast Cancer Reports.2020; 12(4): 391. CrossRef
Clinical Practice Status of Sentinel Lymph Node Biopsy for Early-Stage Breast Cancer Patients in China: A Multicenter Study

Juliang Zhang, Ting Wang, Changjiao Yan, Meiling Huang, Zhimin Fan, Rui Ling
Clinical Epidemiology.2020; Volume 12: 917. CrossRef
Feasibility of preoperative tattooing of percutaneously biopsied axillary lymph node: an experimental pilot study
Abida K. Sattar, Basim Ali, Imrana Masroor, Shaista Afzal, Mohammad Usman Tariq, Romana Idrees, Maseeh Uzzaman, Wardah Khalid
Pilot and Feasibility Studies.2020;[Epub] CrossRef
Effectiveness of preoperative ultrasound-guided charcoal tattooing for localization of metastatic melanoma
Ji Hyun Lee, Hyun Su Kim, Young Cheol Yoon, Min Je Kim, Min Jae Cha, Jung-Han Kim
Ultrasonography.2020; 39(4): 376. CrossRef
To Evaluate the Accuracy of Axillary Staging Using Ultrasound and Ultrasound-Guided Fine-Needle Aspiration Cytology (USG-FNAC) in Early Breast Cancer Patients—a Prospective Study
Rashpal Singh, S. V. S. Deo, Ekta Dhamija, Sandeep Mathur, Sanjay Thulkar
Indian Journal of Surgical Oncology.2020; 11(4): 726. CrossRef
Leveraging Neoadjuvant Chemotherapy to Minimize the Burden of Axillary Surgery: a Review of Current Strategies and Surgical Techniques
Alison Laws, Michelle C. Specht
Current Breast Cancer Reports.2020; 12(4): 317. CrossRef
Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer
Janine M. Simons, Thiemo J. A. van Nijnatten, Carmen C. van der Pol, Ernest J. T. Luiten, Linetta B. Koppert, Marjolein L. Smidt
Annals of Surgery.2019; 269(3): 432. CrossRef
Axillary Lymph Node Tattooing and Targeted Axillary Dissection in Breast Cancer Patients Who Presented as cN+ Before Neoadjuvant Chemotherapy and Became cN0 After Treatment
Ioannis Natsiopoulos, Stavros Intzes, Triantafyllos Liappis, Konstantinos Zarampoukas, Thomas Zarampoukas, Vasiliki Zacharopoulou, Konstantinos Papazisis
Clinical Breast Cancer.2019; 19(3): 208. CrossRef
Pretreatment Tattoo Marking of Suspicious Axillary Lymph Nodes: Reliability and Correlation with Sentinel Lymph Node
Rupa Patel, Wendy MacKerricher, Jacqueline Tsai, Nicole Choy, Jafi Lipson, Debra Ikeda, Sunita Pal, Wendy De Martini, Kimberly H. Allison, Irene L. Wapnir
Annals of Surgical Oncology.2019; 26(8): 2452. CrossRef
Node positive breast cancer: Concordance between baseline PET/CT and sentinel node assessment after neoadjuvant therapy
Oscar Leopoldo Christin, Jonathan Kuten, Einat Even-Sapir, Joseph Klausner, Tehillah S. Menes
Surgical Oncology.2019; 30: 1. CrossRef
Sentinel Node Lymph Node Surgery After Neoadjuvant Therapy: Principles and Techniques
Jennifer M. Racz, Abigail S. Caudle
Annals of Surgical Oncology.2019; 26(10): 3040. CrossRef
Excision of both pretreatment marked positive nodes and sentinel nodes improves axillary staging after neoadjuvant systemic therapy in breast cancer
J M Simons, M L M A van Pelt, A W K S Marinelli, M E Straver, A M Zeillemaker, L M Pereira Arias-Bouda, T J A van Nijnatten, L B Koppert, K K Hunt, M L Smidt, E J T Luiten, C C van der Pol
British Journal of Surgery.2019; 106(12): 1632. CrossRef
Ultrasound-guided dual-localization for axillary nodes before and after neoadjuvant chemotherapy with clip and activated charcoal in breast cancer patients: a feasibility study
Won Hwa Kim, Hye Jung Kim, See Hyung Kim, Jin Hyang Jung, Ho Yong Park, Jeeyeon Lee, Wan Wook Kim, Ji Young Park, Yee Soo Chae, Soo Jung Lee
BMC Cancer.2019;[Epub] CrossRef
Conservative Management of Positive Axilla After Neoadjuvant Systemic Therapy—The Need for, and Review of, Techniques Used for Lymph Node Localization
Matthew Green, Foteini Neamonitou, Raghavan Vidya
Clinical Breast Cancer.2018; 18(5): e739. CrossRef
Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint
Judy C. Boughey, Michael D. Alvarado, Rachael B. Lancaster, W. Fraser Symmans, Rita Mukhtar, Jasmine M. Wong, Cheryl A. Ewing, David A. Potter, Todd M. Tuttle, Tina J. Hieken, Jodi M. Carter, James W. Jakub, Henry G. Kaplan, Claire L. Buchanan, Nora T. Ja
npj Breast Cancer.2018;[Epub] CrossRef

16,834 View
368 Download
63 Web of Science
62 Crossref

Risk Factors for a False-Negative Result of Sentinel Node Biopsy in Patients with Clinically Node-Negative Breast Cancer: Seung Ah Lee, Hak Min Lee, Hak Woo Lee, Ban Seok Yang, Jong Tae Park, Sung Gwe Ahn, Joon Jeong, Seung Il Kim; Cancer Res Treat. 2018;50(3):625-633. Published online July 31, 2017; DOI: https://doi.org/10.4143/crt.2017.089

Abstract PDF Supplementary Material PubReader ePub

Purpose
Although sentinel lymph node biopsy (SLNB) can accurately represent the axillary lymph node (ALN) status, the false-negative rate (FNR) of SLNB is the main concern in the patients who receive SLNB alone instead of ALN dissection (ALND).
Materials and Methods
We analyzed 1,886 patientswho underwent ALNDafter negative results of SLNB,retrospectively. A logistic regression analysis was used to identify risk factors associated with a falsenegative (FN) result. Cox regression model was used to estimate the hazard ratio of factors affecting disease-free survival (DFS).
Results
Tumor located in the upper outer portion of the breast, lymphovascular invasion, suspicious node in imaging assessment and less than three sentinel lymph nodes (SLNs) were significant independent risk factors for FN in SLNB conferring an adjusted odds ratio of 2.10 (95% confidence interval [CI], 1.30 to 3.39), 2.69 (95% CI, 1.47 to 4.91), 2.59 (95% CI, 1.62 to 4.14), and 2.39 (95% CI, 1.45 to 3.95), respectively. The prognostic factors affecting DFS were tumor size larger than 2 cm (hazard ratio [HR], 1.86; 95% CI, 1.17 to 2.96) and FN of SLNB (HR, 2.51; 95% CI, 1.42 to 4.42) in SLN-negative group (FN and true-negative), but in ALN-positive group (FN and true-positive), FN of SLNB (HR, 0.64; 95% CI, 0.33 to 1.25) did not affect DFS.
Conclusion
In patients with risk factors for a FN such as suspicious node in imaging assessment, upper outer breast cancer, less than three harvested nodes, we need attention to find another metastatic focus in non-SLNs during the operation. It may contribute to provide an exact prognosis and optimizing adjuvant treatments.

Citations

Citations to this article as recorded by

Axillary staging with 18F-FDG PET/CT in early breast cancer: impact of tumor subtypes
Abdullah Gunes, Nuray Colapkulu-Akgul, Caner Akgul, Ibrahim Unlu, Saffet Cinar
Annals of Saudi Medicine.2025; 45(3): 145. CrossRef
Establishment of Prediction Model of Axillary Lymph Node Metastasis Before Operation for Early-Stage Breast Cancer
Xinhua Zhang, Chuang Zhang, Jian Zhang, Xiuming Zhang, Xiaowen Dou
Cancer Control.2025;[Epub] CrossRef
Potential factors of false-negative sentinel lymph node biopsy for breast cancer and clinical decision-making value of axillary lymph node dissection
Jianghai Li, Dong Meng
BMC Surgery.2025;[Epub] CrossRef
Detection of presence or absence of metastasis in WSI patches of breast cancer using the dual-enhanced convolutional ensemble neural network
Ruigang Ge, Guoyue Chen, Kazuki Saruta, Yuki Terata
Machine Learning with Applications.2024; 17: 100579. CrossRef
Ultrasound radiomics based on axillary lymph nodes images for predicting lymph node metastasis in breast cancer
Yu-Long Tang, Bin Wang, Tao Ou-Yang, Wen-Zhi Lv, Shi-Chu Tang, An Wei, Xin-Wu Cui, Jiang-Sheng Huang
Frontiers in Oncology.2023;[Epub] CrossRef
Future Directions in the Assessment of Axillary Lymph Nodes in Patients with Breast Cancer
Filippo Pesapane, Luciano Mariano, Francesca Magnoni, Anna Rotili, Davide Pupo, Luca Nicosia, Anna Carla Bozzini, Silvia Penco, Antuono Latronico, Maria Pizzamiglio, Giovanni Corso, Enrico Cassano
Medicina.2023; 59(9): 1544. CrossRef
Axillary Lymph Node Dissection Can Be Omitted in Breast Cancer Patients With Mastectomy and False-Negative Frozen Section in Sentinel Lymph Node Biopsy
Jing Si, Rong Guo, Huan Pan, Xiang Lu, Zhiqin Guo, Chao Han, Li Xue, Dan Xing, Wanxin Wu, Caiping Chen
Frontiers in Oncology.2022;[Epub] CrossRef
False-negative frozen section of sentinel nodes in early breast cancer (cT1-2N0) patients
Zhu-Jun Loh, Kuo-Ting Lee, Ya-Ping Chen, Yao-Lung Kuo, Wei-Pang Chung, Ya-Ting Hsu, Chien-Chang Huang, Hui-Ping Hsu
World Journal of Surgical Oncology.2021;[Epub] CrossRef
What Is High-risk Breast Cancer With Pathologically Negative Lymph Nodes for Regional Recurrence?
Sang-Won Kim, Won Kyung Cho, Doo Ho Choi, Haeyoung Kim, Oyeon Cho, Won Park, Mison Chun
International Journal of Radiation Oncology*Biology*Physics.2021; 111(4): 992. CrossRef
Validating the ACOSOG Z0011 Trial Result: A Population-Based Study Using the SEER Database
Jiwoong Jung, Byoung Hyuck Kim, Jongjin Kim, Sohee Oh, Su-jin Kim, Chang-Sup Lim, In Sil Choi, Ki-Tae Hwang
Cancers.2020; 12(4): 950. CrossRef
Retrospectively validating the results of the ACOSOG Z0011 trial in a large Asian Z0011-eligible cohort
Jiwoong Jung, Wonshik Han, Eun Sook Lee, So-Youn Jung, Jai Hong Han, Dong-Young Noh, Yumi Kim, Hee Jun Choi, Jeong Eon Lee, Seok Jin Nam, Jong Won Lee, Hee Jeong Kim, Eunhae Um, Joo Heung Kim, Seho Park, Young Up Cho
Breast Cancer Research and Treatment.2019; 175(1): 203. CrossRef
Preliminary study of contrast-enhanced ultrasound in combination with blue dye vs. indocyanine green fluorescence, in combination with blue dye for sentinel lymph node biopsy in breast cancer
Yidong Zhou, Yan Li, Feng Mao, Jing Zhang, Qingli Zhu, Songjie Shen, Yan Lin, Xiaohui Zhang, He Liu, Mengsu Xiao, Yuxin Jiang, Qiang Sun
BMC Cancer.2019;[Epub] CrossRef

16,812 View
357 Download
13 Web of Science
12 Crossref

¹⁸F-FDG/PET May Help to Identify a Subgroup of Patients with T1-T2 Breast Cancer and 1-3 Positive Lymph Nodes Who Are at a High Risk of Recurrence after Mastectomy: Jee Suk Chang, Jeongshim Lee, Hyun Jung Kim, Kyung Hwan Kim, Mijin Yun, Seung Il Kim, Ki Chang Keum, Chang-Ok Suh, Yong Bae Kim; Cancer Res Treat. 2016;48(2):508-517. Published online September 9, 2015; DOI: https://doi.org/10.4143/crt.2015.172

Abstract PDF PubReader ePub

Purpose
The purpose of this study is to assess the utility of positron emission tomography (PET) for predicting recurrence among patients with T1-T2/N1 breast cancer who were treated with mastectomy. Materials and Methods Of 712 consecutive patients with T1-T2/N1 breast cancer treated during 2003-2012, 109 had undergone preoperative 18F-fluorodeoxyglucose/PET and were included. Metabolic (maximum standardized uptake value [SUVmax]), volumetric (metabolic tumor volume [MTV]), and combined (total lesion glycolysis [TLG]) indices were measured. The resulting values were analyzed and compared with clinical outcome.
Results
At the median follow-up of 46.7 months, the 3-year relapse-free survival (RFS) rate was 95.2%. SUVmax (area under curve, 0.824) was more useful than MTV or TLG as a means of identifying patients at high risk for any recurrence. In multivariate analysis, SUVmax remained an independent risk factor for RFS (p=0.006). Using the method of Contal and O’Quigley, a SUVmax threshold of 5.36 showed the best predictive performance. The PET-based highrisk group (≥ 5.36 in either breast or nodes) had more T1c-T2, high-grade, hormone-receptor negative, and invasive ductal carcinoma tumors than the low-risk group (< 5.36 in both breast and nodes). The prognosis was much worse when high SUVmax (≥ 5.36) was detected in nodes (p < 0.001). In the no-radiotherapy cohort, the PET-based high-risk group had increased risk of locoregional recurrence when compared to the low-risk group (p=0.037). Conclusion High SUVmax on preoperative PET showed association with elevated risk of locoregional recurrence and any recurrence. Pre-treatment PET may improve assessments of recurrence risk and clarify indications for post-mastectomy radiotherapy in this subset of patients.

Citations

Citations to this article as recorded by

Subcutaneous/cutaneous uptake in the cancer-affected breast on 18F-FDG PET/CT: association with post-surgical prognosis in breast cancer patients
Yurika Kitano, Kanae K. Miyake, Tomomi W. Nobashi, Takayoshi Ishimori, Ryusuke Nakamoto, Sho Koyasu, Masako Kataoka, Yasuhide Takeuchi, Masakazu Toi, Yuji Nakamoto
Annals of Nuclear Medicine.2026; 40(1): 73. CrossRef
Locoregional indicators of systemic spread in breast cancer: insights from standard-of-care imaging and ¹⁸F-FDG PET/CT
Yurika Kitano, Kanae K. Miyake, Tomomi W. Nobashi, Takayoshi Ishimori, Ryusuke Nakamoto, Sho Koyasu, Masako Kataoka, Masakazu Toi, Yuji Nakamoto
Annals of Nuclear Medicine.2026; 40(3): 272. CrossRef
Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Early Standardized Uptake Value Reduction in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy
Soong June Bae, Sung Gwe Ahn, Jung Hwan Ji, Chih Hao Chu, Dooreh Kim, Janghee Lee, Soeun Park, Chihwan Cha, Joon Jeong
Journal of Breast Cancer.2022; 25(6): 485. CrossRef
Significance of Metabolic Tumor Volume at Baseline and Reduction of Mean Standardized Uptake Value in 18F-FDG-PET/CT Imaging for Predicting Pathological Complete Response in Breast Cancers Treated with Preoperative Chemotherapy
Tomoko Higuchi, Yukie Fujimoto, Hiromi Ozawa, Ayako Bun, Reiko Fukui, Yoshimasa Miyagawa, Michiko Imamura, Kazuhiro Kitajima, Koichiro Yamakado, Yasuo Miyoshi
Annals of Surgical Oncology.2019; 26(7): 2175. CrossRef
The ability of pre-treatment F-18 FDG PET/CT metabolic parameters for predicting axillary lymph node and distant metastasis and overall survival
Burcak Yilmaz, Sedef Dağ, Nurhan Ergul, Tevfik Fikret Çermik
Nuclear Medicine Communications.2019; 40(11): 1112. CrossRef
Postmastectomy radiotherapy in T1-2 patients with one to three positive lymph nodes – Past, present and future
Filip Kaššák, Christine Rossier, Cristina Picardi, Jacques Bernier
The Breast.2019; 48: 73. CrossRef
The prognostic value of SUVmax measuring on primary lesion and ALN by 18F-FDG PET or PET/CT in patients with breast cancer
Wei Diao, Fangfang Tian, Zhiyun Jia
European Journal of Radiology.2018; 105: 1. CrossRef
Differential Prognostic Impact of Strong PD-L1 Expression and 18F-FDG Uptake in Triple-negative Breast Cancer
Seo Hee Choi, Jee Suk Chang, Ja Seung Koo, Jong Won Park, Joo Hyuk Sohn, Ki Chang Keum, Chang-Ok Suh, Yong Bae Kim
American Journal of Clinical Oncology.2018; 41(11): 1049. CrossRef
Prediction of breast cancer recurrence using lymph node metabolic and volumetric parameters from 18F-FDG PET/CT in operable triple-negative breast cancer
Yong-il Kim, Yong Joong Kim, Jin Chul Paeng, Gi Jeong Cheon, Dong Soo Lee, June-Key Chung, Keon Wook Kang
European Journal of Nuclear Medicine and Molecular Imaging.2017; 44(11): 1787. CrossRef
Tumor size and proliferative marker geminin rather than Ki67 expression levels significantly associated with maximum uptake of 18F-deoxyglucose levels on positron emission tomography for breast cancers
Arisa Nishimukai, Natsuko Inoue, Ayako Kira, Masashi Takeda, Koji Morimoto, Kazuhiro Araki, Kazuhiro Kitajima, Takahiro Watanabe, Seiichi Hirota, Toyomasa Katagiri, Shoji Nakamori, Kouhei Akazawa, Yasuo Miyoshi, Renato Franco
PLOS ONE.2017; 12(9): e0184508. CrossRef
Prognostic Value of SUVmax of <sup>18</sup>F-FDG PET/CT in Early Stage Breast Cancer with No LN Metastasis
Ryusuke Murakami, Yoshimitsu Fukushima, Hitomi Tani, Kotomi Iwata, Shinichiro Kumita, Maki Nakai, Tomoko Kurita, Keiko Yanagihara, Hiroyuki Takei, Miyuki Matsubara
Open Journal of Medical Imaging.2017; 07(03): 112. CrossRef
Volume-based metabolic parameter of breast cancer on preoperative 18F-FDG PET/CT could predict axillary lymph node metastasis
Young-Sil An, Doo Kyoung Kang, Yongsik Jung, Tae Hee Kim
Medicine.2017; 96(45): e8557. CrossRef
Trends in the Application of Postmastectomy Radiotherapy for Breast Cancer With 1 to 3 Positive Axillary Nodes and Tumors ≤5 cm in the Modern Treatment Era
Jee Suk Chang, Jung Eun Choi, Min Ho Park, Sung Hoo Jung, Byung Ock Choi, Hyung Seok Park, Seho Park, Yong Bae Kim
Medicine.2016; 95(19): e3592. CrossRef
Prognostic significance of preoperative 18F-FDG PET/CT for breast cancer subtypes
Tomoko Higuchi, Arisa Nishimukai, Hiromi Ozawa, Yukie Fujimoto, Ayako Yanai, Yoshimasa Miyagawa, Keiko Murase, Michiko Imamura, Yuichi Takatsuka, Kazuhiro Kitajima, Kazuhito Fukushima, Yasuo Miyoshi
The Breast.2016; 30: 5. CrossRef

15,024 View
106 Download
13 Web of Science
14 Crossref

First
Prev
Page of 1
Next
Last

Search